Daniel A. Camardo

Daniel A. Camardo, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Horizon Therapeutics Public Ltd Co, Athersys, INC / NEW and Cue Biopharma, Inc. In total, 24 filings cover trades dated from 1 October 2020 to 9 July 2026.

The open-market side counts 2 purchases for €146k alongside 5 sales for €1.2M. Netting one side against the other leaves €1.0M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 11 share grants and 6 option exercises.

Most recently, on 10 July 2026, the filings show a share grant in Cue Biopharma, Inc. The latest purchase dates back some time: it was published 1,432 days ago, on 22 November 2022. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.